... WhatsApp

How Urine Tumor DNA Can Predict Bladder Cancer Recurrence After Immunotherapy

You are here >> Home > Latest Updates > Urinary Bladder Cancer > How Urine…

Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-DOI- 10.1016j.eururo.2025.03.023

For patients with bladder cancer that doesn’t respond to BCG treatment, a new urine test might help doctors choose the best next steps.

In a recent study, researchers looked at people with early bladder cancer who received an immunotherapy drug called atezolizumab. They tested urine samples for tumor DNA using a method called UroAmp. This test looks for tiny bits of cancer DNA that the bladder sheds into urine.

The results were striking. Patients with no tumor DNA in their urine at the start had much better outcomes. Most of them were still cancer-free after 18 months. But patients with detectable tumor DNA were more likely to have their cancer return.

Even patients who seemed to be doing well after 3 months were at higher risk if their urine still had tumor DNA.

This urine test may become an important tool for doctors. It can help decide who might benefit from continuing treatment and who might need a different approach.

If you’re facing bladder cancer that hasn’t responded to BCG, ask your doctor if urine tumor DNA testing is an option for you.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.